Demographics of allogeneic HCT recipients
Demographic . | Data . | |
---|---|---|
Total | 263 | |
Median follow-up (IQR), mo | 16.0 (6.9-30.1) | |
Mean age (range), y | 60.0 (21.7-78.4) | |
HCT-CI | ||
0-1 | 80 (30) | |
2 | 43 (16) | |
3+ | 140 (53) | |
Conditioning | ||
Ablative | 173 (66) | |
Reduced or nonmyeloablative | 90 (34) | |
Diagnosis | ||
AML | 167 (63) | |
MDS | 96 (37) | |
HLA match | ||
8/8 | 248 (94) | |
7/8 | 15 (6) | |
GVHD prophylaxis | ||
CD34+ selection | 121 (46.0) | |
Calcineurin inhibitor based | 142 (54.0) | |
Refined disease risk index | ||
Low/intermediate | 142 (54.0) | |
High | 91 (34.6) | |
Very high | 30 (11.4) |
Demographic . | Data . | |
---|---|---|
Total | 263 | |
Median follow-up (IQR), mo | 16.0 (6.9-30.1) | |
Mean age (range), y | 60.0 (21.7-78.4) | |
HCT-CI | ||
0-1 | 80 (30) | |
2 | 43 (16) | |
3+ | 140 (53) | |
Conditioning | ||
Ablative | 173 (66) | |
Reduced or nonmyeloablative | 90 (34) | |
Diagnosis | ||
AML | 167 (63) | |
MDS | 96 (37) | |
HLA match | ||
8/8 | 248 (94) | |
7/8 | 15 (6) | |
GVHD prophylaxis | ||
CD34+ selection | 121 (46.0) | |
Calcineurin inhibitor based | 142 (54.0) | |
Refined disease risk index | ||
Low/intermediate | 142 (54.0) | |
High | 91 (34.6) | |
Very high | 30 (11.4) |
Data are number of patients (percentage of total transplant recipients), unless otherwise stated.